For example, CRISPR/Cas9-mediated deletion of CD33 in HSPCs preserved hematopoietic function while rendering cells resistant to CD33-directed CAR T cell cytotoxicity, enabling leukemia clearance without prolonged myelosuppression [100,101,102]. This evidence concerns the gene CD33 and leukemia.